EA201791518A1 - Способы лечения заболеваний сетчатки - Google Patents

Способы лечения заболеваний сетчатки

Info

Publication number
EA201791518A1
EA201791518A1 EA201791518A EA201791518A EA201791518A1 EA 201791518 A1 EA201791518 A1 EA 201791518A1 EA 201791518 A EA201791518 A EA 201791518A EA 201791518 A EA201791518 A EA 201791518A EA 201791518 A1 EA201791518 A1 EA 201791518A1
Authority
EA
Eurasian Patent Office
Prior art keywords
subject
cells
retail
methods
treat diseases
Prior art date
Application number
EA201791518A
Other languages
English (en)
Inventor
Эйяль Банин
Бенджамин Этан Рубинофф
Оснат Бохана-Каштан
Нир Нетзер
Чарльз Шерард Ирвинг
Original Assignee
Селл Кьюр Нейросайансес Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56284392&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201791518(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Селл Кьюр Нейросайансес Лтд. filed Critical Селл Кьюр Нейросайансес Лтд.
Publication of EA201791518A1 publication Critical patent/EA201791518A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/00727—Apparatus for retinal reattachment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Surgery (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Раскрыт способ лечения субъекта с сухой формой возрастной макулярной дегенерации (AMD). Способ предусматривает введение в субретинальное пространство субъекта терапевтически эффективного количества фармацевтической композиции, содержащей клетки RPE человека, причем по меньшей мере 95% указанных клеток коэкспрессируют премеланосомный протеин (PMEL17) и клеточный ретинальдегид-связывающий белок (CRALBP), причем трансэпителиальное электрическое сопротивление клеток составляет более чем 100 Ом по отношению к субъекту, тем самым обеспечивая лечение субъекта.
EA201791518A 2014-12-30 2015-04-30 Способы лечения заболеваний сетчатки EA201791518A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462097753P 2014-12-30 2014-12-30
US201562116980P 2015-02-17 2015-02-17
US201562116972P 2015-02-17 2015-02-17
PCT/IL2015/050456 WO2016108219A1 (en) 2014-12-30 2015-04-30 Methods of treating retinal diseases

Publications (1)

Publication Number Publication Date
EA201791518A1 true EA201791518A1 (ru) 2017-10-31

Family

ID=56284392

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791518A EA201791518A1 (ru) 2014-12-30 2015-04-30 Способы лечения заболеваний сетчатки

Country Status (18)

Country Link
US (2) US20180008458A1 (ru)
EP (1) EP3240612B1 (ru)
JP (4) JP2018501281A (ru)
KR (2) KR102359257B1 (ru)
CN (3) CN114533761A (ru)
AU (3) AU2015373111B2 (ru)
BR (1) BR112017014332A2 (ru)
CA (2) CA2972700A1 (ru)
DK (1) DK3240612T3 (ru)
EA (1) EA201791518A1 (ru)
ES (1) ES2843626T3 (ru)
HK (1) HK1246179A1 (ru)
IL (1) IL253244B2 (ru)
MX (1) MX2017008818A (ru)
PH (1) PH12017501217A1 (ru)
SG (1) SG11201705378RA (ru)
WO (1) WO2016108219A1 (ru)
ZA (1) ZA201704359B (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011063005A2 (en) 2009-11-17 2011-05-26 Advanced Cell Technology, Inc. Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells
IL305070A (en) 2014-12-30 2023-10-01 Cell Cure Neurosciences Ltd RPE cell populations and methods for their production
CN114533761A (zh) 2014-12-30 2022-05-27 细胞治疗神经科学有限公司 治疗视网膜疾病的方法
US20180011092A1 (en) 2014-12-30 2018-01-11 Cell Cure Neurosciences Ltd. Assessing retinal pigment epithelial cell populations
JP7055095B2 (ja) 2015-07-29 2022-04-15 ハダシット メディカル リサーチ サービシーズ アンド ディベロップメント リミテッド 網膜色素上皮細胞の大規模生産
EP3331995A1 (en) * 2015-08-05 2018-06-13 Cell Cure Neurosciences Ltd. Preparation of photoreceptors for the treatment of retinal diseases
WO2018170494A1 (en) * 2017-03-16 2018-09-20 Bio Time, Inc. Methods for measuring therapeutic effects of retinal disease therapies
AU2018308976A1 (en) 2017-07-31 2020-02-20 Biotime, Inc. Compositions and methods for restoring or preventing loss of vision caused by disease or traumatic injury
WO2019130061A2 (en) * 2017-12-29 2019-07-04 Cell Cure Neurosciences Ltd. Retinal pigment epithelium cell compositions
CN108795864B (zh) * 2018-05-24 2021-08-24 中山大学中山眼科中心 一种利用人诱导多能干细胞获得富含视锥及视杆细胞的类视网膜组织的方法
US10264436B1 (en) * 2018-05-29 2019-04-16 Link Labs, Inc. BLE networking systems and methods providing central and peripheral role reversal with independent peripheral network connectivity
AU2019328577A1 (en) * 2018-08-31 2021-03-11 University Of Florida Research Foundation, Incorporated Adeno-associated viral vectors for the treatment of best disease
WO2020229628A1 (en) * 2019-05-15 2020-11-19 Novo Nordisk A/S Methods for obtaining eye field progenitor cells from human pluripotent stem cells
EP4208187A1 (en) * 2020-09-03 2023-07-12 Curebiotec GmbH Pigment epithelium-derived factor (pedf) for use in treatment of macular degeneration or choroidal neovascularisation
EP3964227A1 (en) * 2020-09-08 2022-03-09 Curebiotec GmbH Method for the treatment of a disease using pigment epithelium-derived factor (pedf)
KR102633321B1 (ko) * 2021-05-11 2024-02-05 연세대학교 산학협력단 노인성 황반변성의 예방 또는 치료를 위한 약학 조성물
CN115212233B (zh) * 2022-08-26 2024-05-28 北京市眼科研究所 用于治疗视网膜相关疾病的组合物、试剂盒及其应用
WO2024110625A1 (en) * 2022-11-24 2024-05-30 Universität Bern Cralbp based therapeutics for retinal disorders

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
EP2554661B2 (en) 2007-04-18 2018-02-21 Hadasit Medical Research Services & Development Limited Stem cell-derived retinal pigment epithelial cells
CN104946591A (zh) * 2007-10-12 2015-09-30 奥卡塔治疗公司 制备rpe 细胞和rpe 细胞的组合物的改良方法
KR101025880B1 (ko) * 2008-10-23 2011-03-30 공희숙 성체 줄기세포를 이용한 인슐린 분비세포로의 분화 유도방법
WO2011063005A2 (en) * 2009-11-17 2011-05-26 Advanced Cell Technology, Inc. Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells
CA2855941A1 (en) * 2011-11-14 2013-05-23 Advanced Cell Technology, Inc. Pharmaceutical preparations of human rpe cells and uses thereof
US9850463B2 (en) * 2012-02-01 2017-12-26 The Regents Of The University Of California Methods of culturing retinal pigmented epithelium cells, including xeno-free production, RPE enrichment, and cryopreservation
KR101483988B1 (ko) * 2012-04-09 2015-01-28 연세대학교 산학협력단 망막하 주사 또는 추출용 중공형 마이크로니들 및 망막하 주사기
JP6426110B2 (ja) 2013-02-01 2018-11-21 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 人口多能性幹細胞（ｉｐｓｃ）由来の網膜色素上皮（ｒｐｅ）細胞を生成するための方法
KR101871084B1 (ko) * 2013-12-11 2018-06-25 화이자 리미티드 망막 색소 상피 세포의 제조 방법
US20180011092A1 (en) 2014-12-30 2018-01-11 Cell Cure Neurosciences Ltd. Assessing retinal pigment epithelial cell populations
CN114533761A (zh) 2014-12-30 2022-05-27 细胞治疗神经科学有限公司 治疗视网膜疾病的方法
IL305070A (en) 2014-12-30 2023-10-01 Cell Cure Neurosciences Ltd RPE cell populations and methods for their production
KR101982801B1 (ko) * 2015-10-28 2019-05-30 서울대학교 산학협력단 망막색소상피 분화 유도용 조성물

Also Published As

Publication number Publication date
JP2022125160A (ja) 2022-08-26
PH12017501217A1 (en) 2018-01-29
MX2017008818A (es) 2018-03-14
JP2020143137A (ja) 2020-09-10
IL253244B1 (en) 2023-05-01
JP2024023611A (ja) 2024-02-21
KR20170120583A (ko) 2017-10-31
CA2972700A1 (en) 2016-07-07
EP3240612A1 (en) 2017-11-08
US20230028133A1 (en) 2023-01-26
JP2018501281A (ja) 2018-01-18
AU2023255009A1 (en) 2023-11-16
CN114469998A (zh) 2022-05-13
AU2021229196A1 (en) 2021-10-07
IL253244B2 (en) 2023-09-01
CN114533761A (zh) 2022-05-27
SG11201705378RA (en) 2017-08-30
IL253244A0 (en) 2017-08-31
AU2015373111B2 (en) 2021-06-24
ES2843626T3 (es) 2021-07-19
BR112017014332A2 (pt) 2018-01-02
HK1246179A1 (zh) 2018-09-07
KR102359257B1 (ko) 2022-02-07
EP3240612B1 (en) 2020-12-23
KR20220020422A (ko) 2022-02-18
CA3175175A1 (en) 2016-07-07
ZA201704359B (en) 2018-08-29
US20180008458A1 (en) 2018-01-11
EP3240612A4 (en) 2018-06-13
WO2016108219A1 (en) 2016-07-07
AU2015373111A1 (en) 2017-07-13
DK3240612T3 (da) 2021-01-18
CN107427534A (zh) 2017-12-01
KR102514912B1 (ko) 2023-03-27

Similar Documents

Publication Publication Date Title
EA201791518A1 (ru) Способы лечения заболеваний сетчатки
MX2021006581A (es) Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia.
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
WO2016210372A3 (en) Methods to treat neurological diseases
WO2017136795A8 (en) Bacteria engineered to treat diseases associated with tryptophan metabolism
MX2016010328A (es) Tratamiento con halogeno de ataque cardiaco y lesion isquemica.
WO2017139697A8 (en) Bacteria engineered to treat diseases associated with hyperammonemia
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
WO2016200614A3 (en) Bacteria engineered to treat diseases associated with hyperammonemia
MX2022009155A (es) Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh).
MX2021004558A (es) Polimeros de union a protones para administracion oral.
WO2019040106A3 (en) COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES
MX2019001633A (es) Proteina derivada de la seda para el tratamiento de la inflamacion.
WO2016029136A8 (en) 3-amidobenzamides and uses thereof for increasing cellular levels of a3g
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
PH12017500392A1 (en) Medical treatments based on anamorelin
EA201892297A1 (ru) Способы лечения холестатических и фибротических заболеваний
NZ745187A (en) 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
WO2017011356A3 (en) Mcj inhibitors for use in treating drug-induced diseases and conditions
NZ745329A (en) Gene therapy for the treatment of a disease of retinal cone cells
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
WO2019040105A3 (en) COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES
EP3549582A3 (en) Novel capsazepine analogs for the treatment of cancer and other proliferative diseases
SG10201811203TA (en) Protocols for treatment of major depressive disorder (mdd)
RU2017118158A (ru) Средство, стимулирующее продукцию тау-белка, и терапевтическое или профилактическое средство и терапевтическая или профилактическая пищевая композиция, предназначенные для лечения заболеваний, вызванных дефицитом тау-белка